COTA, Inc. and Texas Oncology’s Precision Health Informatics (PHI) have forged a collaboration to transform precision medicine within Texas Oncology’s community cancer centers. Leveraging COTA’s CAILIN™ AI engine, this partnership aims to extract actionable insights from fragmented healthcare data.
Electronic health records (EHRs) provide valuable information but are often unstructured and incomplete. By integrating AI into data analysis, COTA and PHI seek to accelerate precision medicine at the point of care.
PHI, a subsidiary of Texas Oncology, specializes in cancer testing and treatment using genetic information. Texas Oncology, with over 530 physicians and 280 locations, provides comprehensive cancer care and conducts clinical trials.
COTA, Inc., founded by oncologists, focuses on precision cancer care using real-world data. Their analytics platform collaborates with various stakeholders to enhance cancer treatment.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
